Spring 2026
By Caitlin Henault
When Sarah Salter Levy and Steven Levy learned of Dana-Farber Cancer Institute’s plans to build New England’s first inpatient hospital dedicated to adults with cancer, they wanted to be among the first to step forward with philanthropic support. Scheduled to serve patients in 2031 in Boston’s Longwood Medical Area, Dana-Farber’s planned cancer hospital will encompass 450,000 square feet devoted to patient care, including 300 private inpatient rooms, 30 licensed ICU beds, and a 16-bed observation suite. The hospital will also inaugurate a new clinical partnership between Dana-Farber and Beth Israel Deaconess Medical Center (BIDMC).
As longtime supporters of BIDMC, the Levys eagerly embraced this visionary partnership to elevate the standard for cancer care in New England. With a $3 million gift to Dana-Farber’s Future of Cancer Care Fund, the Levys have provided Dana-Farber with funds that will accelerate the development of the future of cancer hospital and innovative services that will define the patient experience, bolster our research enterprise, expand access to care, and improve outcomes for patients with cancer.
“Dana-Farber’s future cancer hospital is perhaps the most transformative opportunity in the medical community that I’ve ever seen—not just in Boston, but in the United States,” said Steven. “We couldn’t pass up the chance to support not just a new building, but what it represents: a powerful collaboration between two of Boston’s best institutions to elevate cancer care for generations to come.”
Designed to adapt to rapid advances in oncology and meet the growing increase in cancer diagnoses, Dana-Farber’s state-of-the-art facility will ensure that patients have timely access to innovative clinical trials, world-class clinical care, and breakthrough therapies tailored to their individual needs. With direct pathways to Dana-Farber’s Yawkey Center for Cancer Care and research enterprise, as well as BIDMC’s broad range of surgical and other specialists, the hospital will enhance Dana-Farber’s visionary total patient care model, delivering seamless, comprehensive, specialized care and personalized treatment protocols directly to each patient’s bedside. “We’re firm believers that sharing information between institutions only helps the greater good,” said Sarah. “We’ve been connected to BIDMC for decades, and we knew now was the perfect time to show our support for Dana-Farber and the tremendous work they are doing as well.”
Dana-Farber’s future cancer hospital is perhaps the most transformative opportunity in the medical community that I’ve ever seen—not just in Boston, but in the United States.
Steven Levy
“When we first shared this vision with Sarah and Steven, their enthusiasm was palpable and inspiring,” says Benjamin L. Ebert, MD, PhD, president and CEO of Dana-Farber and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. “Visionary philanthropy from supporters like the Levys is essential to bringing our innovative care model to life. Together, we will expand what’s possible in cancer care and research—enabling more patients to receive integrated, best-in-class inpatient and outpatient care.”